Anti–Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

• Published in: American journal of ophthalmology Vol. 204; pp. 13 - 18
• Main Authors: Wubben, Thomas J., Johnson, Mark W., Sohn, Elliott H., Peairs, James J., Kay, Christine N., Kim, Stephen J., Gardner, Thomas W., Paulus, Yannis M., Zacks, David N., Steinle, Nathan C., Avery, Robert L., Berrocal, Maria H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2019; Elsevier Limited
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Bevacizumab - administration & dosage; Clinical trials; Diabetes; Diabetic retinopathy; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Disease; Disease Progression; Drug Administration Schedule; Female; Fluorescein Angiography - methods; Follow-Up Studies; Fundus Oculi; Glaucoma; Hemoglobin; Hemorrhage; Humans; Intravitreal Injections; Male; Middle Aged; Ophthalmology; Retina - pathology; Retrospective Studies; Tomography, Optical Coherence - methods; Treatment Outcome; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity; Ann Arbor Michigan

To illustrate that patients with diabetic retinopathy who are treated exclusively with anti–vascular endothelial growth factor (VEGF) therapy and have an interruption in treatment may experience marked progression of disease with potentially devastating visual consequences. Retrospective, multicente...